Skip to main content
. 2022 Aug 19;56(9):731–739. doi: 10.1097/MCG.0000000000001749

TABLE 2.

Overview of (non)Significant Changes in Patient-reported Outcome Measures in Patients With Polycystic Liver Disease Undergoing Various Treatment Options Compared With Baseline

graphic file with name mcg-56-731-g001.jpg

Black = Statistical difference, Dark grey = conflicting findings, Light grey = no statistical, difference, White = no data available.

GI indicates gastrointestinal questionnaire; mTOR, mammalian target of rapamycin; UDCA, ursodeoxycholic acid etc; V2R, vasopressin-2-receptor.